WallStreetZenWallStreetZen

NASDAQ: DXCM
Dexcom Inc Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for DXCM

Based on 10 analysts offering 12 month price targets for Dexcom Inc.
Min Forecast
$83.00+3.05%
Avg Forecast
$317.60+294.34%
Max Forecast
$580.00+620.14%

Should I buy or sell DXCM stock?

Based on 10 analysts offering ratings for Dexcom Inc.
Strong Buy
Strong Buy
5 analysts 50%
Buy
3 analysts 30%
Hold
2 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DXCM stock forecasts and price targets.

DXCM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Raymond James
Bottom 4%
4
BuyMaintains$101.00+25.40%2022-08-01
Morgan Stanley
Bottom 17%
17
HoldMaintains$83.00+3.05%2022-07-29
Piper Sandler
Bottom 6%
6
Strong BuyMaintains$110.00+36.58%2022-07-29
Bernstein
Bottom 32%
32
BuyInitiates Coverage On$105.00+30.37%2022-07-15
BTIG
Top 6%
95
Strong BuyMaintains$105.00+30.37%2022-06-24
Anonymous
Morgan Stanley
HoldMaintains$91.00+12.99%2022-06-15
Citigroup
Top 8%
93
Strong BuyMaintains$525.00+551.85%2022-05-17
Morgan Stanley
Top 4%
97
HoldMaintains$492.00+510.88%2022-04-29
SVB Leerink
Bottom 3%
3
BuyMaintains$500.00+520.81%2022-04-29
Wells Fargo
Bottom 19%
19
Strong BuyUpgrades$575.00+613.93%2022-01-19

1 of 2

Forecast return on equity

Is DXCM forecast to generate an efficient return?
Company
29.24%
Industry
59.3%
Market
121.74%
DXCM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DXCM forecast to generate an efficient return on assets?
Company
12.64%
Industry
13.85%
DXCM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DXCM earnings per share forecast

What is DXCM's earnings per share in the next 3 years based on estimates from 11 analysts?
Avg 1 year Forecast
$0.79+54.3%
Avg 2 year Forecast
$1.10+114.84%
Avg 3 year Forecast
$1.43+179.3%
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

DXCM revenue forecast

What is DXCM's revenue in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$2.9B+8.22%
Avg 2 year Forecast
$3.5B+30.47%
Avg 3 year Forecast
$4.1B+54.35%
DXCM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DXCM earnings growth forecast

How is DXCM forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
40.61%
Industry
25.51%
Market
16.88%
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

DXCM revenue growth forecast

How is DXCM forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
15.45%
Industry
8.25%
Market
8.59%
DXCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DXCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DXCM vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
DXCM$80.54$317.60+294.34%Strong Buy
ILMN$190.79$257.00+34.70%Hold
IQV$181.14$265.67+46.66%Strong Buy
A$121.55$149.33+22.86%Buy
IDXX$325.80$483.57+48.43%Strong Buy
View Top Diagnostic & Research Stocks

Dexcom Stock Forecast FAQ

Is Dexcom Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 10 Wall Street analysts covering (NASDAQ: DXCM) stock is to Strong Buy DXCM stock.

Out of 10 analysts, 5 (50%) are recommending DXCM as a Strong Buy, 3 (30%) are recommending DXCM as a Buy, 2 (20%) are recommending DXCM as a Hold, 0 (0%) are recommending DXCM as a Sell, and 0 (0%) are recommending DXCM as a Strong Sell.

If you're new to stock investing, here's how to buy Dexcom stock.

What is DXCM's earnings growth forecast for 2022-2024?

(NASDAQ: DXCM) Dexcom's forecast annual earnings growth rate of 40.61% is forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 25.51%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Dexcom's earnings in 2022 is $199,700,000.On average, 11 Wall Street analysts forecast DXCM's earnings for 2022 to be $310,139,603, with the lowest DXCM earnings forecast at $278,733,061, and the highest DXCM earnings forecast at $329,768,692. On average, 10 Wall Street analysts forecast DXCM's earnings for 2023 to be $431,839,954, with the lowest DXCM earnings forecast at $353,323,598, and the highest DXCM earnings forecast at $459,320,678.

In 2024, DXCM is forecast to generate $561,391,940 in earnings, with the lowest earnings forecast at $545,688,669 and the highest earnings forecast at $581,021,028.

What is DXCM's revenue growth forecast for 2022-2024?

(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 15.45% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.25%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Dexcom's revenue in 2022 is $2,673,400,000.On average, 8 Wall Street analysts forecast DXCM's revenue for 2022 to be $1,135,764,595,783, with the lowest DXCM revenue forecast at $1,126,366,580,648, and the highest DXCM revenue forecast at $1,145,763,653,618. On average, 8 Wall Street analysts forecast DXCM's revenue for 2023 to be $1,369,360,959,630, with the lowest DXCM revenue forecast at $1,327,168,625,836, and the highest DXCM revenue forecast at $1,433,001,998,755.

In 2024, DXCM is forecast to generate $1,619,915,285,872 in revenue, with the lowest revenue forecast at $1,543,218,154,622 and the highest revenue forecast at $1,693,177,719,164.

What is DXCM's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: DXCM) forecast ROA is 12.64%, which is lower than the forecast US Diagnostics & Research industry average of 13.85%.

What is DXCM's Price Target?

According to 10 Wall Street analysts that have issued a 1 year DXCM price target, the average DXCM price target is $317.60, with the highest DXCM stock price forecast at $580.00 and the lowest DXCM stock price forecast at $83.00.

On average, Wall Street analysts predict that Dexcom's share price could reach $317.60 by Aug 1, 2023. The average Dexcom stock price prediction forecasts a potential upside of 294.34% from the current DXCM share price of $80.54.

What is DXCM's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: DXCM) Dexcom's current Earnings Per Share (EPS) is $0.51. On average, analysts forecast that DXCM's EPS will be $0.79 for 2022, with the lowest EPS forecast at $0.71, and the highest EPS forecast at $0.84. On average, analysts forecast that DXCM's EPS will be $1.10 for 2023, with the lowest EPS forecast at $0.90, and the highest EPS forecast at $1.17. In 2024, DXCM's EPS is forecast to hit $1.43 (min: $1.39, max: $1.48).

What is DXCM's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: DXCM) forecast ROE is 29.24%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.